Yeda R&D — Weizmann Institute's Technology Transfer Company

Yeda Research and Development Company Ltd. is the technology-transfer arm of the Weizmann Institute of Science in Rehovot, Israel. Founded in 1959-60, it is frequently described as the first university technology-transfer company in Israel and one of the first in the world.

Yeda's model: Weizmann scientists disclose inventions to Yeda, which files patents and licenses them to industry partners, returning a share of royalty income to the inventing researchers and reinvesting the remainder in the Institute. Licensed inventions include the multiple-sclerosis drug Copaxone (with Teva), the MS drug Rebif (with Merck Serono), and antibody technologies underlying Humira, Erbitux and Vectibix. Weizmann's own account states that products and IP arising from its research generate roughly $37 billion a year in global sales for the licensee companies — a figure describing downstream product sales, not Yeda's own royalty income, which independent business-press coverage reports separately as over $2 billion in cumulative royalties across a six-year period.

In January 2020, Yeda and Deerfield Management formed a joint venture, Orchard Innovations LLC, with Deerfield committing up to $130 million over ten years to fund Weizmann drug-development projects — a concrete, independently reported transaction.

Evidence caveats: published patent counts vary sharply by source (roughly 500 vs. roughly 2,200 patent families, depending on whether the count is of currently active or cumulative historical filings), and Yeda's own website was unreachable for direct verification during evaluation, so some figures here rely on secondary business-press coverage rather than Yeda's primary disclosures.

Read the full analysis: https://wis-wander.weizmann.ac.il/people-and-events/60-years-yeda-setting-new-records